Close this search box.

Hutchmed names new chairman as Simon To retires

ARTICLE | Management Tracks

Plus: Immunome promotes Max Rosett to CFO, and Mark de Jong becomes CTO at Full-Life

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst   

May 17, 2024 9:59 PM UTC

Hutchmed China Ltd. (LSE:HCM; NASDAQ:HCM; HKEX:0013) announced the retirement of Chairman and Executive Director Simon To after 23 years with the company, and the appointment of Dan Eldar as the new Chair. Eldar is an executive director of Hutchison Water Israel E.P.C Ltd., and has been a non-executive director of Hutchmed since 2016.

Immunome Inc. (NASDAQ:IMNM), which is developing targeted cancer therapies, promoted Max Rosett to CFO from EVP of operations. Rosett joined Immunome in October 2023 as SVP of operations and has served as interim CFO since January…